cinacalcet hydrochloride has been researched along with Hyperparathyroidism in 1 studies
*Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, H; Hisada, Y; Idei, A; Iguchi, T; Ikeda, Y; Kannami, A; Kawata, T; Kifuji, T; Kojima, K; Kuroda, M; Miyake, T; Miyazaki, H; Moritani, Y; Ohashi, R; Okabe, J; Sakairi, T; Sakurai, O; Sato, N; Tokunaga, S; Tsubota, R; Tsukumo, Y; Yanagida, T; Yoneda, H | 1 |
1 other study(ies) available for cinacalcet hydrochloride and Hyperparathyroidism
| Article | Year |
|---|---|
Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.
Topics: Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Discovery; Humans; Hyperparathyroidism; Models, Molecular; Molecular Structure; Pyrrolidines; Rats; Receptors, Calcium-Sensing; Structure-Activity Relationship | 2018 |